Eleutheroside B ameliorated high altitude pulmonary edema by attenuating ferroptosis and necroptosis through Nrf2-antioxidant response signaling - 15/11/22











Abstract |
High altitude pulmonary edema (HAPE) is a potentially fatal condition induced by exposure to high-altitude environment. Eleutheroside B is a naturally active polyphenolic substance that has previously demonstrated anti-inflammatory, antioxidant and antidepressant properties. However, the effects of eleutheroside B on HPAE are unknown. Here, eleutheroside B (50 mg/kg and 100 mg/kg) was applied to HAPE rats. Eleutheroside B alleviated lung edema and decreased levels of tumor necrosis factor-α, interleukin-1β, vascular endothelial growth factor, and total proteins in the bronchoalveolar lavage fluid. Eleutheroside B reversed the acid-base disturbances by HAPE. In addition, eleutheroside B reversed the oxidative stress. Eleutheroside B pretreatment facilitated the translocation of nuclear factor E2-related factor 2 (Nrf2) into the nucleus, contributing to the inhibition of ferroptosis and necroptosis. ML385 confirmed the role of Nrf2 in ferroptosis and necroptosis. Collectively, the beneficial effects of eleutheroside B against HAPE were associated with the inhibition of ferroptosis and necroptosis through Nrf2-antioxidant response signaling.
Le texte complet de cet article est disponible en PDF.Graphical Abstract |
Highlights |
• | Exposure to high altitude altered the nuclear translocation of Nrf2. |
• | Eleutheroside B facilitated Nrf2 translocation to the nucleus in HAPE. |
• | Eleutheroside B inhibited oxidative stress, ferroptosis and necroptosis by activating the nuclear translocation of Nrf2. |
Abbreviations : BALF, CAT, COX2, FTH1, GPX4, HAPE, Hb, HCO3, Hct, HO-1, H&E, IL-1β, Nrf2, Keap1, MDA, MLKL, NF-κB, NOX1, PaCO2, PaO2, PBS, pH, RIPK1, RIPK3, ROS, SaO2, SLC7A11, TEM, TFRC, TNF-α, VEGF, W/D, 4-HNE
Keywords : Eleutheroside B, High-altitude pulmonary edema, Nrf2, Ferroptosis, Necroptosis, Oxidative stress
Plan
Vol 156
Article 113982- décembre 2022 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?